Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 4, 2003, Pages 375-379

  Cardiello, Peter G ^a,b   Monhaphol, Tarkika ^a   Mahanontharit, Apicha ^a   Van Heeswijk, Rolf P ^b   Burger, David ^c   Hill, Andrew ^d   Ruxrungtham, Kiat ^a,e   Lange, Joep M ^b   Cooper, David A ^f   Phanuphak, Praphan ^a,d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b National Antiretroviral Therapy Evaluation Center   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Asia; Hard soft gelatin capsules; Pharmacokinetics drug interactions; Protease inhibitors; Saquinavir

Indexed keywords

DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAXIMUM ALLOWABLE CONCENTRATION; PRIORITY JOURNAL; STEADY STATE; TREATMENT PLANNING;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RITONAVIR; SAQUINAVIR;

EID: 0037377835     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304010-00005     Document Type: Article

References (13)

1. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13:213-224.
2. Fortovase Product Label. Roche Pharmaceuticals, 1998.
3. Perry CM, Noble S. Saquinavir soft-gel capsule formulation: a review of its use in subjects with HIV infection. Drugs. 1998;55: 461-486.
4. Hoetelmans RM, Meenhorst PL, Mulder JW, et al. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997;19:159-175.
5. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001;2:105-113.
6. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther. 1998;63:453-464.
7. Cardiello P, van Heeswijk R, Hassink E, et al. Simplifying protease inhibitor therapy with once daily dosing of saquinavir (soft gel)/ritonavir 1,600/100 mg: HIVNAT 001.3. J Acquir Immune Defic Syndr. 2002;29:464-470.
8. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2001;27:344-349.
9. Reynolds JEF, ed. Martindale. The extra pharmacopoiea. 28th ed. London: The Pharmaceutical Press, 1982.
10. Kroon ED, Ungsedhapand C, Ruxrungtham K, et al. A randomized, double blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected subjects (study HIV-NAT 001). AIDS. 2000;14:1349-1356.
11. Cardiello P, Kroon E, Hoetelmans R, et al. Steady-state pharmacokinetics (PK) of saquinavir (SQV) with and without two doses of itraconazole in HIV-1+ Thai subjects: HIV NAT 001.2 substudy [abstract WeOrB545]. Presented at the XIII International AIDS Conference, Durban, July 2000.
12. Hugen PW, Verweij-van Wissen CP, Burger DM, et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;727:139-149.
13. Hoetelmans RMW, van Heeswijk RPG, Meenhorst PL, et al. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period [abstract 42261]. Presented at the XII International AIDS Conference, Geneva, June-July 1998.